China's Porton Advanced Solutions has announced a strategic cooperation with Suzhou Royaltech Med Co. to jointly promote the establishment of microbial vectors used for gene therapy (MVGTs) (listeria monocytogenes) and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs.

Porton Advanced provides an end-to-end gene and cell therapy CDMO service platform covering plasmids, cell therapy, gene therapy, oncolytic virus, nucleic acid therapy and viable bacteria therapy.

Suzhou Royaltech focuses on the development of vaccines for tumor immunotherapy with its proprietary technologies, and fast  transition from clinical to market. Its R&D pipeline covers the attenuated non-integrated Listeria platform, RNA platform, and cell therapy platform. All these platforms are in the leading position not only in China but also abroad, and have a complete layout of invention patents.

Dr Yangzhou Wang, CEO of Porton Advanced, said, "Porton Advanced's end-to-end gene and cell therapy CDMO platform with rich project experience and comprehensive  quality system will help Royaltech with the development of Listeria and mRNA drugs, push its R&D pipeline in a quick, efficient manner, and accelerate the development and implementation of innovative drugs, so that good medicines can benefit the public earlier."